Charles Michaud
No más puestos en curso
Fortuna: 23 639 $ al 31/05/2024
Historial de carrera de Charles Michaud
Antiguos cargos conocidos de Charles Michaud.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
AOBiome Therapeutics, Inc.
AOBiome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA. | Comptroller/Controller/Auditor | 01/04/2019 | 01/06/2020 |
Q32 BIO INC. | Comptroller/Controller/Auditor | 01/06/2020 | - |
Director Financiero/CFO | 17/11/2023 | - | |
Treasurer | 17/11/2023 | - |
Formación de Charles Michaud.
University of Massachusetts | Undergraduate Degree |
Boston University | Masters Business Admin |
Estadísticas
Internacional
Estados Unidos | 5 |
Operativa
Comptroller/Controller/Auditor | 2 |
Director of Finance/CFO | 1 |
Treasurer | 1 |
Sectorial
Health Technology | 3 |
Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 2 |
---|---|
Homology Medicines, Inc.
Homology Medicines, Inc. Pharmaceuticals: MajorHealth Technology Homology Medicines, Inc. is a clinical-stage genetic medicines company, which engages in the translation of proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. The company was founded in March 2015 and is headquartered in Bedford, MA. | Health Technology |
AOBiome Therapeutics, Inc.
AOBiome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Charles Michaud
- Experiencia